01First entry
Companies entering the US market for the first time
Teams seeking to validate the opportunity, build the right entry model and make clearer investment decisions.
01 — Market analysis
Know the market before entering it.
We turn the complexity of the US market into a clear commercial roadmap shaped around your product, category and growth goals.
US MARKETCommercialization
What we solve
One partner.
At every commercial step.
We help pharmaceutical companies enter, operate and grow in the US market through an integrated commercialization model.
See how we work →01↗
US Market Entry
Opportunity analysis, positioning and an actionable market-entry plan.
02↗
Commercial Strategy
Channel, customer and sales models designed around real market dynamics.
03↗
Sales Operations
Execution, enablement and reporting that keep teams aligned and accountable.
04↗
Market Access
A coordinated approach to access, pricing and stakeholder management.
Our medicines
Explore our
products.
Browse the medicines in our product portfolio or quickly find one by entering its name.
View all medicines →Who we work with
Different stages.
One shared need: clarity.
Our model adapts to commercial needs ranging from first US entry to scaling an established operation.
02Launch
Pharma and biotech companies preparing to launch
Organizations bringing channel, team, partner and operational readiness into one launch plan.
03Scale
Teams scaling their US operation
Companies seeking visibility, coordination and measurable performance gains across an existing commercial structure.
INSIGHTS
Expert perspectives for
the US pharmaceutical market.
Expert-reviewed perspectives that support clearer decisions across FDA-regulated market entry and commercialization.
View all insights →Commercial Strategy
How to Build a Commercial Strategy for a US Pharmaceutical Launch
Build an actionable US launch strategy connecting positioning, priority customers, channels, field model and measurable performance.
August 18, 2026 · 1 min readRead insight →US Market Entry
A US Pharmaceutical Market Entry Roadmap for International Companies
Structure US market entry around opportunity validation, the regulatory pathway, operating model, partners and measurable launch readiness.
August 18, 2026 · 1 min readRead insight →FDA & Regulatory
FDA Approval, NDA and ANDA: A Starting Guide for International Pharma Companies
Understand what NDA and ANDA pathways mean, when commercial readiness should begin and which early decisions shape US pharmaceutical market entry.
August 18, 2026 · 2 min readRead insight →Frequently asked questions
Complete clarity
before the first step.
Questions international pharmaceutical companies most often ask while preparing to enter or grow in the US market.
Ask another question →01When should a pharmaceutical company begin planning US market entry?
Commercial planning should ideally begin well ahead of launch. Starting early creates time to validate the opportunity, shape channel strategy and build a realistic operating plan.
02Do you support companies without a US commercial team?
Yes. We can operate as an extension of your international leadership team, help establish the commercial model, coordinate specialist partners and provide clear oversight of US operations.
03Which parts of commercialization can you manage?
Our model connects market assessment, launch readiness, channel and sales operations, partner coordination and ongoing performance management.
04Can you work with our existing US partners?
Absolutely. We can coordinate your agencies, distributors and specialist service providers so every workflow follows one strategy and reporting rhythm.
For determined teams
